ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRDN Viridian Therapeutics Inc

12.88
0.18 (1.42%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 538,173
Bid Price 11.21
Ask Price 14.50
News -
Day High 13.06

Low
10.925

52 Week Range

High
28.99

Day Low 12.43
Company Name Stock Ticker Symbol Market Type
Viridian Therapeutics Inc VRDN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 1.42% 12.88 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.74 12.43 13.06 12.88 12.70
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,844 538,173 $ 12.91 $ 6,949,721 - 10.925 - 28.99
Last Trade Time Type Quantity Stock Price Currency
16:20:00 formt 475 $ 12.88 USD

Viridian Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
808.45M 62.77M - 314k -237.73M -3.79 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Viridian Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VRDN Message Board. Create One! See More Posts on VRDN Message Board See More Message Board Posts

Historical VRDN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.0915.5212.2013.84914,092-2.21-14.65%
1 Month17.6917.6912.2015.39757,137-4.81-27.19%
3 Months19.5921.4612.2017.55907,531-6.71-34.25%
6 Months11.7624.1811.0118.07928,5521.129.52%
1 Year27.9928.9910.92519.09820,470-15.11-53.98%
3 Years17.8039.009.4720.62505,707-4.92-27.64%
5 Years21.3939.009.4720.60467,067-8.51-39.78%

Viridian Therapeutics Description

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Your Recent History

Delayed Upgrade Clock